This public notice, issued by the Central Drugs Standard Control Organization (CDSCO) under the Directorate General of Health Services, addresses the illegal manufacture and misuse of oxytocin in India. To address this issue, CDSCO has established a system to receive and monitor complaints centrally. The public is encouraged to report instances of illegal oxytocin production and misuse via email to biologicalcdsco.nic.in or dci@nic.in, or by submitting complaints in the designated Complaint Box at the reception of CDSCO HQ, FDA Bhawan, Kotla Road, New Delhi-110002. The notice is issued under the authority of Dr. G.N. Singh, Drugs Controller General of India, on March 30, 2011, with reference number BDVET.CELL 042017.
Key Entities Referenced
Directorate of General of Health Services: An organization, likely under the Ministry of Health and Family Welfare, Government of India.
Central Drugs Standard Control Organization: The national regulatory body for pharmaceuticals and medical devices in India.
FDA Bhawan, Kotla Road, New Delhi: Location of the CDSCO Headquarters, New Delhi, Delhi.
oxytocin: A hormone and medication subject to regulatory control due to concerns about illegal manufacture and misuse.
CDSCO: Abbreviation for Central Drugs Standard Control Organization. It is the central regulatory body in India responsible for drug regulation.
Dr. GN. Singh: The Drugs Controller General of India at the time of the notice.
Drugs Controller General India: The head of the Central Drugs Standard Control Organization (CDSCO) in India.
F. No: BD/VET.CELL/ 04-2017
Directorate of General of Health Services
Central Drugs Standard Control Organization
FDA Bhawan, Kotla Road, New Delhi
(O/o DCG (I))
30 MAR 2011
PUBLIC NOTICE
Subject: Strict regulatory control over manufacture, sale and distribution of oxytocin
and to curb its misuse -reg.
In order to curb the illegal manufacture and misuse of oxytocin in the country, a system
has been created in CDSCO to receive complaints in such matter so that these complaints
are monitored at the Central level.
It is for the information that complaints regarding illegal production of oxytocin and its
misuse may be sent through E-mail biological@cdsco.nic.in or dci@nic.in or dropped in the
Complaint Box placed at the reception of the CDSCO (HQ), FDA Bhawan, Kotla Road, New
Delhi-110002 for the purpose.
(Dr. G/N. Singh)
Drugs Controller General (India)